Safety and Efficacy of TKI258 in Relapsed or Refractory Multiple Myeloma Patients, Who Are With or Without t(4;14) Chromosomal Translocation
This study will evaluate safety and efficacy of TKI258 in patients with relapsed or refractory multiple myeloma
Relapsed or Refractory Multiple Myeloma
DRUG: TKI258
Overall response rate, 4 weeks
frequency and severity of adverse events as per CTCAE, throughout the study|Progression free survival (PFS), every 4 weeks|Plasma exposure of TKI258, during the first 3 cycles
This study will evaluate safety and efficacy of TKI258 in patients with relapsed or refractory multiple myeloma